Glaxosmithkline Biologicals Sa

Novartis Ag

Novartis Vaccines and Diagnostics Srl

Maurizio Comanducci

Maria Arico

Mariagrazia Pizza

Vega Masignani

Maria Scarselli

Cesira Galeotti

Rino Rappuoli

Marzia Monica Giuliani

Marizia Monica Guiliani

Nathalie Norais

Manuele Martinelli

Marco Soriani

Rosanna Leuzzi

Gillian Douce

Giuseppe Ercoli

Chiara Tani

Marzia Monica Guiliani

Mazia Monica Giuliani

Gram-negative bacterial strains are generated by inactivating at least one LytM catalytic domain-containing protein, such as NT013, NT017 and NT022 of non typeable. The vesicles from these strains are useful for vaccination.

Mutant bacteria for production of generalized modules for membrane antigens

The present invention relates to recombinant fragments ofTcdA and TcdB that may be used in the development of vaccines againstassociated disease. More particularly it relates to combinations comprising a ToxB-GT antigen and a TcdA antigen or a ToxA-GT antigen and a TcdB antigen.

Clostridium difficile toxin-based vaccine

fHBP is a protein in. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.

Meningococcal fHBP polypeptides

NadA, App and ORF40 function as adhesins in. Adhesion nad be modulated by targeting these three proteins. NadA allelic variants are also disclosed. Autoproteolytic cleavage of App is disclosed, as is removal of the activity by mutagenesis. App is processed and secreted into culture medium when expressed in. Mature App proteins are disclosed. Knockout mutants are disclosed. Vesicles from non-Neisserial hosts with heterologous adhesion expression are disclosed.

Meningococcus adhesins NadA, App and ORF 40

Alternative and improved approaches to the heterologous expression of the proteins ofand. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.

Heterologous expression of neisserial proteins

Heterologous expression of Neisserial proteins

Growing community of inventors

Poggibonsi, Italy

Maria Arico